BOSTON and NEW YORK, Dec. 3,
2021 /PRNewswire/ -- GreenLight Biosciences (ENVI) and
IAVI, a nonprofit scientific research organization, today announced
work on a messenger RNA vaccine candidate to tackle the COVID-19
Omicron variant.
"The highly mutated Omicron variant may be partially capable of
eluding existing vaccines, so rapid adaptation is an urgent
priority," said GreenLight CEO Andrey
Zarur. "We have started lab work already. We will be testing
a new candidate vaccine shortly in preclinical models. We have also
begun an analysis on how we would proceed in clinical studies in
Africa, in the context of our
current clinical plans."
IAVI President and CEO Mark
Feinberg said, "While it's impossible to say right now where
Omicron first emerged, we wouldn't have been able to respond to
this threat so quickly had it not been for the skill and openness
of the South African scientists who identified the variant and
shared the sequence with the world. Now we must focus on bringing
solutions forward both to address this new variant and the stark
inequities that remain in the global availability of vaccines to
prevent COVID-19."
On November 30, GreenLight and
IAVI announced their plans to partner to advance GreenLight's
messenger RNA COVID-19 vaccine candidate in a Phase I clinical
trial, with IAVI responsible for clinical trial management in
collaboration with its network of clinical research center partners
in sub-Saharan Africa. The flexibility of the messenger RNA
platform has allowed GreenLight to advance new variant-adjusted
vaccine candidates.
Notes to editors
About GreenLight
Founded in 2008, GreenLight aims to solve some of the world's
biggest problems by delivering on the full potential of RNA for
human health and agriculture.
In human health, this includes mRNA vaccines and therapeutics.
In agriculture, this includes RNA to protect honeybees and a
range of crops. The company's breakthrough cell-free RNA
manufacturing platform, which is protected by numerous patents,
allows for cost-effective and scalable production of RNA. For more
information, visit https://www.greenlightbiosciences.com/
In August 2021, GreenLight
Biosciences announced plans to become publicly listed through a
business combination with Environmental Impact Acquisition Corp.
(Nasdaq: ENVI).
About IAVI
IAVI is a nonprofit scientific research organization with
headquarters in the U.S. and locations in Europe, Africa, and India that develops vaccines and antibodies
for HIV, tuberculosis, emerging infectious diseases (including
COVID-19), and neglected diseases, with the goal of global access.
Read more at iavi.org.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, with respect to the
proposed transaction between GreenLight Biosciences, Inc.
("GreenLight") and Environmental Impact Acquisition Corp. ("ENVI").
These forward-looking statements generally are identified by the
words "believe," "project," "expect," "anticipate," "estimate,"
"intend," "strategy," "future," "opportunity," "plan," "may,"
"should," "will," "would," "will be," "will continue," "will likely
result" and similar expressions. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to the
risk that the transaction may not be completed in a timely manner
or at all, which may adversely affect the price of ENVI's
securities and the effect of the announcement or pendency of the
transaction on GreenLight's business relationships, operating
results, and business generally. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and ENVI and
GreenLight assume no obligation and do not intend to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/greenlight-envi-and-iavi-begin-work-on-omicron-variant-adapted-covid-19-vaccine-candidate-301437412.html
SOURCE GreenLight Biosciences, Inc.